Navigation Links
Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting

1 EOquin Instillation Immediately Following Transurethral Resection is Well Tolerated in Phase 2b Bladder Cancer Study

IRVINE, Calif., April 19, 2007 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc., today announced results of a Phase 2b study of EOquin, in non-invasive bladder cancer and the presentation of preclinical data of SPI (IRL)-1620 and satraplatin at the annual meeting of the American Association of Cancer Research, held at the Los Angeles Convention Center in Los Angeles, California April 14-18, 2007.

Abstract #LB-359 -- Effect on Wound Healing and Pharmacokinetics of Single Intravesical Administration of Apaziquone (EOquin(R)) Immediately Following Transurethral Resection of Superficial Bladder Cancer -- Initial Results of a Phase 2b Study

The Phase 2b study was a multicenter, single-arm, open-label safety study with the objective of assessing the effect on surgical wound healing and systemic absorption of EOquin when given intravesically as a single dose immediately after transurethral resection of bladder tumor (TUR-BT). EOquin in 40mL of instillate was instilled into the bladder within 6 hours of TUR-BT. After an hour, the bladder was drained and patients were assessed for adverse events during the one-hour retention. Wound healing was assessed by cystoscopy performed at postoperative day 85.

Results

A total of 23 patients were enrolled and 20 patients received EOquin immediately following TUR-BT. EOquin instillation and retention were well tolerated by all patients, and no deaths or dropouts were reported. Four Serious Adverse Events were reported in three patients: two hematuria, one bacterial cystitis, and one urinary retention. Ten patients were examined by cystoscopy at day 85 and all showed complete reepithelialization without evidence of impaired wound healing. Neither the parent drug (EO9) nor its metabolite (EO54a) was detected in plasma samples utili
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
2. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:1/23/2015)... , Jan. 23, 2015  A new analysis of ... D 2015 enrollment data shows that 81 percent of ... access and extra discounts at certain pharmacies. The findings ... "Preferred pharmacy plans are now the foundation of Medicare ...
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
(Date:1/23/2015)... 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the ... Lixte,s lead compound, LB‑100, is being conducted, has been expanded ... Kovach , M.D., the founder and President of Lixte, said ... a single site. Accrual of patients, however, was slower than ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... Dec. 2, 2010 United Seating & Mobility (USM) ... suppliers, is excited to announce today that it has finalized ...   The transaction applies to Fridley, MN serving ... Milwaukee Area, and Appleton, WI; RehabTECH will continue to operate ...
... (OTC Bulletin Board: CDXC ), a leader ... research services, today announced that it has entered into ... to supply analytical reference standards, quality control methods and ... raw materials and finished goods. "With increasing ...
Cached Medicine Technology:ChromaDex Partners With Kappa Bioscience to Provide Quality Control Methods, Tools and Services for Vitamin K2 2
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 Joan ... and keynote speaker at the upcoming 32nd Annual ... ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , shares ... would have gone undetected if she had not followed ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
(Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
(Date:1/22/2015)... As interest in the value of spiritual support as ... Rev. Eric J. Hall , president and CEO of the ... the keynote speaker on January 27 at an international summit ... The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual Care,” ...
Breaking Medicine News(10 mins):Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... years ago, the first Ronald McDonald House(R) opened its ... home" for families with seriously ill children. Today, McDonald,s(R) ... celebration to commemorate this important milestone and their long-standing ... , , "For 35 years, local McDonald,s franchisees ...
... For more than 30 years, consumers have benefited from the ... effects of the sun, including sun burn, premature skin aging, ... efficacy of sunscreen products have been thoroughly studied and tested ... is an extensive body of credible scientific research that demonstrates ...
... scientists, patients and members of the biotech industry from around ... unique research center on muscular dystrophy -- the Senator Paul ... , Established last year and based at Boston Biomedical Research ... Center and the only center in the world to focus ...
... Discovery may help explain why disease runs in families, , ... to inherited testicular germ-cell cancer has been identified by scientists ... contributes to our understanding of why testicular germ-cell cancer appears ... said in an agency news release. "The findings may also ...
... published in the July issue of The Journal ... (PET) scans in mice can be used to determine ... working as intended. Researchers successfully used PET and a ... with aggressive breast cancerin breast cancer cells before and ...
... NEW BRUNSWICK, N.J. and DUBLIN, July 2 Johnson & ... (NYSE: ELN ) today announced a definitive agreement ... assets and rights of Elan related to its Alzheimer,s Immunotherapy ... addition, Johnson & Johnson, through its affiliate, will invest $1 ...
Cached Medicine News:Health News:Ronald McDonald House Charities(R) (RMHC(R)) and McDonald's(R) Seek Inspiring Stories Through New 'Share.Give.Hope.' Campaign 2Health News:Ronald McDonald House Charities(R) (RMHC(R)) and McDonald's(R) Seek Inspiring Stories Through New 'Share.Give.Hope.' Campaign 3Health News:Statement by John Bailey, Chief Scientist The Personal Care Products Council, Response to EWG's 2009 Sunscreen Report 2Health News:Statement by John Bailey, Chief Scientist The Personal Care Products Council, Response to EWG's 2009 Sunscreen Report 3Health News:Statement by John Bailey, Chief Scientist The Personal Care Products Council, Response to EWG's 2009 Sunscreen Report 4Health News:Statement by John Bailey, Chief Scientist The Personal Care Products Council, Response to EWG's 2009 Sunscreen Report 5Health News:Successful Beginning for Wellstone Muscular Dystrophy Center at Boston Biomedical Research Institute 2Health News:Another Genetic Link to Testicular Cancer Is Found 2Health News:Study shows PET can measure effectiveness of novel breast cancer treatment 2Health News:Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment 2Health News:Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment 3Health News:Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment 4Health News:Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment 5
... Performance beyond your investment., ,The Centiva/5 Critical ... and time demands of the critical care environment. ... in mind combining a compact size with high ... up valuable space around the patients bed and ...
... Although other treatments for ,ED (e.g. ... used today, ,Vacuum Therapy is ... and their physicians ,because of the very ... should be used as a daily ,exercise ...
... is combining a lightweight mesh material with the ... hernia plug which stands for a high patient ... material is included in Premilene Mesh LP Self-Forming ... for a softer and less bulky Plug Premilene ...
... a mesh plug to treat large or ... hernias and femoralhernias. The self-expanding plug perfectly ... completely. Premilene Mesh Self-Forming Plug is a ... Mesh. The plug corresponds with all properties ...
Medicine Products: